"Pharmaceutical Express" China Biopharmaceuticals to be listed on the Cottro board Bayer's new inhibitors...

February 4, 2021 / Medical Information List: China Biopharmaceuticals is to be listed on the Cottro board; Daily fresh medicine news, speed reading society and you pay attention to! Part1 policy brief Jilin added 8 new locally confirmed cases February 3 0-24, Jilin Province newly found confirmed cases 2 cases (Changchun City 1 case, Tonghua City 1 case), are through the isolation of medical observers to carry out active testing screening found;
(Jilin Health Commission) Shanghai new local confirmed cases 3 cases February 3 0-24 hours, Shanghai new local new crown pneumonia confirmed cases 3 cases.
two of the confirmed cases are in Huangpu District and one confirmed case is in Baoshan District.
has now implemented centralized isolation medical observation for all contacts related to 3 cases.
have been disinfected at sites where the cases have been active.
(Shanghai Health Commission) Beijing for 5 consecutive days local zero new February 3 from 0:00 to 24:00, Beijing no new local confirmed cases, suspected cases and asymptomatic infections;
(Beijing Health and Safety Commission) the fourth batch of national collection of the results of the election was announced on February 3, the fourth batch of state-organized drug centralized procurement in Shanghai for bidding, the evening of the results of the proposed winning bid has been made public.
According to CCTV news reports, the procurement of a total of 45 kinds of drugs, all successful procurement, the proposed drug price reduction of an average of 52%, involving hypertension, diabetes, digestive diseases, mental diseases, malignant tumors and other therapeutic fields.
(CCTV News) Electronic medical record system evaluation came on February 3, the National Health And Wellness Commission Hospital Management Research Institute issued the "National Health and Health Commission Hospital Management Research Institute on the issuance of electronic medical record system application level evaluation procedures and expert management methods notice."
"Notice" pointed out that the Hospital Research Institute in accordance with the "institutionalized, paperless, closed-loop" management principles, the development of "electronic medical records classification evaluation platform" and to provincial units and medical institutions to open up the corresponding authority.
on the evening of February 3rd, China Biopharmaceuticals announced that the board had approved preliminary proposals for a possible RMB share issue and listing on the Shanghai Stock Exchange.
domestic issues are subject to market conditions, shareholder approval at the Company's general meeting of shareholders, and necessary regulatory approval.
(China Biopharmaceuticals Announcement) Haihe Pharmaceuticals filed an IPO application on the SSE, the latest publicity shows that Haihe Pharmaceuticals has submitted an IPO application to The Science and Technology Board, and was accepted on February 3.
according to the prospectus, Haihe Pharmaceuticals this time adopted the fifth set of listing standards of the board, the number of shares to be issued publicly does not exceed 221 million shares, the plan is to raise 3.15 billion yuan.
(SSE) 150 million euros to develop the next generation of mRNA new crown vaccine GlaxoSmithKline today, GlaxoSmithKline and CureVac announced that the two sides will build on the existing cooperation to develop a new 150 million euro cooperation to develop the next generation of mRNA new crown vaccine, which has the potential to use a multi-price vaccine strategy in one vaccine to provide protection against multiple new crown mutation strains.
's acquisition of GW on February 4th, Jazz announced that it would buy GW, the UK pharmaceutical company that listed its first cannabidiol preparation, for $6.7bn in cash, a 50 per cent premium to yesterday's closing price.
GW's main product is TheDravet syndrome drug Epidiolex, which sold $500 million last year.
(U.S. and Chinese medicine source) Sage Smart received 10 million yuan pre-A round financing artery network the first time to know that Yan Sheng Smart recently completed 10 million yuan pre-A round of financing, this round of financing led by Meihua Ventures, old shareholder Yuanyi Capital continues to follow investment, Beito Capital is the financial advisor of this round of financing.
that the current round of financing will be mainly used for the continuous upgrading and marketing of the quality control products of the Sage Smart AI case.
(Arterial Network) Tencent led the investment, Microyuan Gene received 200 million yuan C round financing artery network was the first to learn that Microyuan Gene recently announced the completion of 200 million yuan C round financing.
this round of financing is led by Tencent, with the participation of existing shareholders such as CHINA Capital, Dingyi Investment, Guoke Jia and others.
this is a new round of financing within six months after micro-gene completed the 200 million yuan B round of financing in August 2020.
(Arterial Network) Part3 drug news Noshing Jianhua pan FGFR inhibitor ICP-192 in the United States completed the first trial of the subject drug Noshing Jianhua announced today, in the study of the new drug Pan FGFR inhibitor ICP-192 in the United States completed the first patient drug.
ICP-192 is a class 1 innovative drug with global independent intellectual property rights, is a highly selective small molecule pan-FGFR inhibitor for the treatment of multiple solid tumors, and is currently conducting a number of clinical studies in China and the United States.
(Xinhua) -- The FDA has accelerated the approval of Merck's MET inhibitors for sale today, and Merck's EMD Serono announced that the U.S. FDA has accelerated the approval of oral MET inhibitor Tepmetko for the treatment of adult patients with metastasis non-small cell lung cancer with the 14-hop variant of met exons.
(Drug Mingkangde) Yangzijiang injection with leitte qusser approved production and treated as a review day ago, Yangzijiang to imitate the 3 categories of reported injection of thunderous pythons approved production and as the first in the country.
is a thymus synthase inhibitor that is clinically suitable for advanced colorectal cancer that is not suitable for 5-Fu/calcium florate when the patient is unable to receive combined chemotherapy.
(Minenet) Howson Pharmaceuticals meth sulfonate dabiga group ester capsules were approved for production and as before the evaluation, Jiangsu Haussen Pharmaceuticals to imitate the 4 categories of reported methyl sulfonate dabiga ester capsules were approved for production and as a review, as the second domestic.
is a β-alanine coagulase inhibitor used to prevent stroke and systemic embolism in patients with non-valve atrial fibrillation.
(Minenet) Haisco: obtained the registration certificate of innovative drug cyclophenol injection drug February 3, Haisco announced that the wholly-owned subsidiary Liaoning Haisco Pharmaceuticals recently received the NMPA approved the issuance of the "drug registration certificate", the drug name is cyclopolyol injection.
company obtained the "sedative in the endoscopy of the digestive tract" drug registration certificate in December 2020, and the "general anaesthetic induction" of the allergy was approved in February 2021.
(Hesco Announcement) Hundred Times Mercer's innovative blood disease drug Luspatercept listing application by CDE priority review of hundreds of times Meishi Guibao China announced that its red blood cell mature agent Luspatercept listing application has been formally accepted by the NMPA Drug Review Center and was granted priority review qualification for adult β-thalassemia patients who need regular infusion of red blood cells.
(Hundred Times Medical Air Compressor) David Medical Air Compressor was "Medical Device Registration Certificate" February 4, David Medical Announcement, the company's new product medical air compressor was issued by the Zhejiang Provincial Drug Administration "Medical Device Registration Certificate."
the product for medical institutions, the production of medical compressed air, for ventilators or similar breathing systems to provide compressed air sources.
(David Medical Bulletin) Pharmaceuticals and Seymru Reached a CAR-T Strategic Partnership in China on February 3, Andersen announced in a press release that it has reached a strategic partnership with Seamer Fly on the non-exclusive commercial use rights of the latter Gibco™ CTS™ Dynabeads™ CD3/CD28 beads.
cooperation will further promote the clinical development and commercial production of CAR-T therapies in China, such as Reki Oronse injections, the main product of the drug Ming Juno.
(Pharma Mission) GlaxoSmithKline suspended the development of several cancer and rare disease drugs, GlaxoSmithKline released its fourth quarter and full-year financial results, including the company will suspend research and development of drugs in the new quarter.
these drugs include GSK3174998, which has been used to treat tumors, and GSK2330811, an anti-OSM drug used to treat systemic sclerosis, and Benlysta-Rituxan, which is used for dry syndrome.
addition, GlaxoSmithKline partner Immutep said earlier this month that it would also suspend the research drug GSK2831781 for the phase 2 trial of ulcerative colitis.
(Sina Pharmaceutical News) Biogen abandoned the Parkinson's drug cimpanemab on February 3, Yan Jian announced in its 2020 annual results and earnings report that the high-profile Parkinson's disease candidate drug cimpanemab in Phase 2 clinical research SPARK did not reach the primary and secondary endpoint.
the development of cipanemab has been halted because the treatment "does not achieve proof-of-concept" and does not provide benefits to patients in the study.
(Sina Medical News)